Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ticilimumab + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy comprised of **ticilimumab**, a monoclonal antibody targeting the T-cell immunoglobulin and ITIM domain (TIGIT) checkpoint, and **gemcitabine**, a small molecule chemotherapeutic agent. Ticilimumab is designed to block immune inhibitory signals mediated by TIGIT, thus enhancing antitumor T-cell activity as part of immunotherapy approaches. Gemcitabine is a nucleoside analog used in the chemotherapy of various solid tumors, operating via inhibition of DNA synthesis and promotion of tumor cell death. This investigational regimen aims to exploit potential synergy between immune checkpoint blockade and cytotoxic chemotherapy, which may increase the activation of antitumor T cells and reduce tumor-associated immune suppression.
- Other names
- ticilimumab + gemcitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA polymerase familyTIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on ticilimumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ticilimumab + gemcitabine.